FOLH1 and neoplasm: While the DOTA derivative showed comparable performance to the inhibitors previously described by Banerjee et al., the HBED-CC conjugate (PSMA-11) provided a significantly improved internalisation in LNCaP cells, resulting in a higher tumour uptake of 7.7%ID/g 1 h p.i. Although PSMA-11 was not a feasible agent for therapeutic approaches, it was still implemented as a diagnostic tracer, with great clinical impact and recent FDA approval [86,87].